Mike Pishvaian
mpishvaian.bsky.social
GI Oncologist at Johns Hopkins, focusing on #PancreaticCancer and #PrecisionMedicine. Striving to improve patient outcomes. Originator of #TumorBoardTuesday @tumorboardtuesday.bsky.social @TumorBoardTues
👤 Joined on 30 November 2024
420
Followers
252
Following
95
Total Posts
📜 Kullanıcı Geçmişi
- 30 Kas 2024, 14:23
🎉 Bluesky'e katıldı - İlk kullanıcı adı:
@mpishvaian.bsky.social
🚫 Blokladığı Kullanıcılar
❤️ Beğendiği Gönderiler
7/18 #TumorBoardTuesday 👩🏻🏫Mini Tweetorial 4🏫 💊Several FDA👍PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib 🤔 When and how do you PIK one of the PIK3CA of the 3 available? ☝️Inavolisib+Fulvestrant+Palbo is approved for 1st line mER+ BC after recurrence on/after adjuvant ET therapy
Show Post7/18 #TumorBoardTuesday 👩🏻🏫Mini Tweetorial 4🏫 💊Several FDA👍PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib 🤔 When and how do you PIK one of the PIK3CA of the 3 available? ✌️Alpelisib & Capivasertib are approved in 2nd line mER+ BC combined with fulvestrant 🔎 NGS results, Baseline A1C
Show Post7/18 #TumorBoardTuesday 👩🏻🏫Mini Tweetorial 4🏫 💊Several FDA approved PIK3CA-inhibitors: Capivasertib or Alpelisib or Inalvosalib 🤔 When and how do you PIK one of the PIK3CA of the 3 available? 📎 pubmed.ncbi.nlm.nih.gov/33246021/
Show Post8/18 #TumorBoardTuesday Back to our case🔎 👩🦳 Patient received Capivasertib + Fulvestrant due to PIK3CA mutation. 👉 Not yet considered endocrine resistant so would not move onto capecitabine, sacituzumab 👉 Tumor is HER2 negative so no role for trastuzumab deruxtecan
Show Post8/18 #TumorBoardTuesday Back to our case🔎 👉 Everolimus + fulvestrant is not favored given the more targeted approach with Capivasterib for the PIK3CA mutation ✅ Tolerated therapy well with mild rash at start of treatment that resolved with antihistamines
Show Post